Getting a leg up on diabetic lower limb amputation with new AI risk prediction model
SINGAPORE, May 13, 2026 /PRNewswire/ -- Personalised risk-based monitoring may soon be the norm for patients with diabetes at high risk of lower extremity amputation (LEA). Jointly developed by Singapore General Hospital (SGH), SingHealth, and the MOH Office for Healthcare Transformation (MOHT), the LEA – Neural Network Model (LEA-Net) harnesses artificial intelligence to...
New Survey Reveals that Singaporeans Know More about Dementia But Nearly 7 in 10 are Unsure Where to Seek Help
Third national survey by SMU on dementia found that stigma persists; despite rising awareness, preparedness remains below neutral SINGAPORE, May 13, 2026 /PRNewswire/ -- Singaporeans are significantly more aware of dementia than they were five years ago, but most still do not know where to turn for help, according to a new...
Herbalife and Cristiano Ronaldo Bring Performance Nutrition to Everyday Routines with “Fuel Like Ronaldo” Campaign
Backed by more than 20 years of experience fueling elite athletes, Herbalife brings its proven performance nutrition expertise to wellness seekers worldwide HONG KONG, May 13, 2026 /PRNewswire/ -- Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, announced the launch of its "Fuel Like Ronaldo" campaign,...
New Nature Communications Publication Highlights Efsubaglutide Alfa’s Effects on Glycaemia and β-Cell Function
HONG KONG, May 13, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-acting GLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin, while also demonstrating favorable β-cell functional responses. The study was led by Academician Weiping Jia and co-corresponded...
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 13, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging...
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
SAN FRANCISCO and SUZHOU, China, May 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from mazdutide and its next‑generation obesity and...
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody...
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
New kit offers researchers and development teams a meaningful advance in expression speed and output BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the...
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and operational biotherapeutics consulting, recently announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration...
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding. This latest round of investment will accelerate the company's...
